•
Jun 30, 2024

Voyager Therapeutics Q2 2024 Earnings Report

Total Revenue
$29.6M
Previous year: $4.85M
+509.5%
EPS
-$0.18
Previous year: -$0.51
-64.7%
Gross Profit
$28.2M
Previous year: $3.77M
+648.2%
Cash and Equivalents
$371M
Previous year: $273M
+36.0%
Free Cash Flow
-$32.5M
Previous year: -$2.05M
+1491.5%
Total Assets
$436M
Previous year: $316M
+38.2%

Voyager Therapeutics

Voyager Therapeutics